At the time of writing, Akero Therapeutics Inc [AKRO] stock is trading at $28.40, down -1.08%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The AKRO shares have lost -2.17% over the last week, with a monthly amount drifted -8.48%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Akero Therapeutics Inc [NASDAQ: AKRO] stock has seen the most recent analyst activity on November 18, 2024, when Citigroup initiated its Buy rating and assigned the stock a price target of $65. On September 19, 2023, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $69 on the stock. UBS started tracking the stock assigning a Buy rating and suggested a price target of $83 on August 28, 2023. Morgan Stanley upgraded its rating to a Overweight and raised its price target to $65 on January 27, 2023. Evercore ISI upgraded its rating to Outperform for this stock on September 14, 2022, and upped its price target to $50. In a note dated October 19, 2021, Morgan Stanley downgraded an Equal-Weight rating on this stock but restated the target price of $27.
For the past year, the stock price of Akero Therapeutics Inc fluctuated between $15.32 and $37.00. Currently, Wall Street analysts expect the stock to reach $50 within the next 12 months. Akero Therapeutics Inc [NASDAQ: AKRO] shares were valued at $28.40 at the most recent close of the market. An investor can expect a potential return of 76.06% based on the average AKRO price forecast.
Analyzing the AKRO fundamentals
Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -948.14%, Pretax Profit Margin comes in at -835.29%, and Net Profit Margin reading is -835.29%. To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.33 and Total Capital is -0.35. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 27.49 points at the first support level, and at 26.57 for the second support level. However, for the 1st resistance point, the stock is sitting at 29.18, and for the 2nd resistance point, it is at 29.96.
Ratios To Look Out For
It is important to note that Akero Therapeutics Inc [NASDAQ:AKRO] has a current ratio of 17.25. As well, the Quick Ratio is 17.25, while the Cash Ratio is 7.3.
Transactions by insiders
Recent insider trading involved Lamy Patrick, Senior VP, Commercial Strategy, that happened on Dec 16 ’24 when 1000.0 shares were sold. Chief Development Officer, Yale Catriona completed a deal on Dec 16 ’24 to sell 9074.0 shares. Meanwhile, Chief Scientific Officer Rolph Timothy sold 3800.0 shares on Dec 17 ’24.
